Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  ZACCARDELLI DAVID
 2. Date of Event Requiring Statement (Month/Day/Year)
01/01/2015		 3. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [UTHR]
(Last)
(First)
(Middle)
C/O UNITED THERAPEUTICS CORP., 1040 SPRING STREET		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
EVP & Chief Operating Officer
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

SILVER SPRING, MD 20910		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 1,153
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Share Tracking Award (1) 01/02/2018(2) 01/02/2023 Common Stock 100,000 $ 53.83 D  
Share Tracking Award (1) 03/14/2015(3) 03/14/2024 Common Stock 50,000 $ 94.96 D  
Share Tracking Award (1) 03/15/2011(4) 03/15/2020 Common Stock 32,928 $ 57.15 D  
Share Tracking Award (1) 03/15/2012(5) 03/15/2021 Common Stock 75,000 (6) $ 65.8 D  
Share Tracking Award (1) 03/15/2013(7) 03/15/2022 Common Stock 22,000 (8) $ 47.5 D  
Share Tracking Award (1) 03/15/2014(9) 03/15/2023 Common Stock 46,000 (10) $ 61.06 D  
Share Tracking Award (1) 09/15/2011(11) 09/15/2020 Common Stock 25,000 $ 51.37 D  
Share Tracking Award (1) 09/15/2010(12) 09/15/2019 Common Stock 26,958 $ 50.09 (13) D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
ZACCARDELLI DAVID
C/O UNITED THERAPEUTICS CORP.
1040 SPRING STREET
SILVER SPRING, MD 20910		       EVP & Chief Operating Officer  

Signatures

/s/ John S. Hess, Jr. under Power of Attorney 01/02/2015
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Share tracking awards settle in cash only upon exercise.
(2) Award granted January 2, 2013. Entire award vests fully on January 2, 2018.
(3) Award granted on March 14, 2014, and vests in one-fourth increments on each of March 14, 2015, 2016, 2017 and 2018.
(4) Award granted on March 15, 2010, and vested in one-fourth increments on each of March 15, 2011, 2012, 2013 and 2014.
(5) Award granted on March 15, 2011, and vests in one-fourth increments on each of March 15, 2012, 2013, 2014 and 2015.
(6) Represents 56,250 vested awards and 18,750 awards scheduled to vest on March 15, 2015.
(7) Award granted on March 15, 2012, and vests in one-fourth increments on each of March 15, 2013, 2014, 2015 and 2016.
(8) Represents 500 vested awards and 21,500 awards that have not yet vested.
(9) Award granted on March 15, 2013, and vests in one-fourth increments on each of March 15, 2014, 2015, 2016 and 2017.
(10) Represents 11,500 vested awards and 34,500 awards that have not yet vested.
(11) Award granted on September 15, 2010, and vested in one-fourth increments on each of September 15, 2011, 2012, 2013 and 2014.
(12) Award granted on September 15, 2009, and vested in one-third increments on each of September 15, 2010, 2011 and 2012.
(13) Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009.
 
Remarks:
Reporting person became subject to Section 16 reporting on January 1, 2015, upon his promotion to EVP and Chief Operating Officer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.